Genomenon Alternatives

Expert-coded by chemists and engineered by computer scientists, SYNTHIA™ Retrosynthesis Software enables scientists to quickly find and easily navigate innovative and novel pathways for novel and published target molecules. Quickly and efficiently scan hundreds of pathways to help you identify the best option according to your needs. Explore the most cost-effective routes to your target molecules with state of the art visualization and filtering options. Easily customize search parameters to eliminate or promote reactions, reagents or classes of molecules. Explore unique and innovative syntheses that may be unknown for building your desired molecule. Easily generate a list of commercially available starting materials for your synthesis. Benefit from ISO/IEC 27001 Information Security Certification to guarantee the confidentiality, integrity, and protection of your data.

Mend is an enterprise-grade patient engagement and telehealth platform designed to help healthcare organizations profitably scale their practice and care for more patients. Founded in 2014, Mend is on a mission to revolutionize healthcare delivery so that every patient can receive extraordinary care. Mend makes it easy for healthcare providers to securely and efficiently communicate with their patients and colleagues, without concerns of violating HIPAA compliance or misplacing patient information. Mend provides integrated in-office and virtual care experiences for over 100 specialties with more than 5 million patients. Mend's comprehensive platform works hand-in-hand with all major EHR and PMS software to facilitate more than 400,000 telehealth visits per month, increase patient satisfaction by up to 23%, reduce no-show rates as low as 4%, radically improve staff productivity, and help providers drive more revenue through better patient attendance.

Leverage the power of AI to expedite the journey from bench research and laboratory insights to the launch of life-changing therapies. Gain up to 90% in research productivity by reducing your reading time from months to minutes. Cut through the noise with a high-precision, high-accuracy search to navigate the ever-growing volume of scientific literature with ease. Save time, reduce bias and increase odds of novel discoveries. Deeply explore disease biology and conduct advanced target discovery. Causaly’s high-precision knowledge graph consolidates evidence from millions of publications, making deep, unbiased scientific exploration possible. Rapidly navigate biological cause-and-effect relationships without being an expert. Get a view of all scientific documents and uncover hidden connections. Causaly’s powerful AI machine reads millions of published biomedical literature to support better decision-making and research outcomes.

We integrate clinical and experimental data using machine learning to navigate human disease biology and advance precision medicines. Our patent-pending Contingent AI™ understands relationships within the data to provide sophisticated insights. We address data bias by iterating on machine learning models based upon decisions made in the pre-processing and feature engineering stages. We leverage zebrafish, cellular and other phenotypic animal models to validate in silico predictions in vivo experiments and genetically modify them in vitro and in vivo, to improve translation. Using active learning and computer vision on validated models for cardiac, central nervous system and rare disorders, we rapidly incorporate new data into our machine learning models.

BIOiSIMTM is a first-in-class 'virtual drug development engine' that offers unprecedented value for the drug development industry by narrowing down the number of drug compounds that offer anticipated value for the treatment or cure of specific illnesses or diseases. We offer a range of translational-based solutions, customized for your pre-clinical and clinical programs. These offerings are all centered around our proven and validated BIOiSIMTM platform for small molecules, large molecules, and viruses. Our models are built on data from thousands of compounds across 7 species, leading to robustness rarely seen in the industry. With a focus on human outcomes, the platform has at its core a translatability engine that transforms insights across species. The BIOiSIMTM platform can be used before the preclinical animal trial start, allowing earlier insights and savings in expensive outsourced experimentation.

Clara’s domain-specific tools, AI pre-trained models, and accelerated applications are enabling AI breakthroughs in numerous fields, including medical devices, imaging, drug discovery, and genomics. Explore the end-to-end pipeline of medical device development and deployment with the Holoscan platform. Build containerized AI apps with the Holoscan SDK and MONAI, and streamline deployment in next-generation AI devices with the NVIDIA IGX developer kits. The NVIDIA Holoscan SDK includes healthcare-specific acceleration libraries, pre-trained AI models, and reference applications for computational medical devices.

Kanteron Platform ingested medical images, digital pathology slides, genomics sequences, and patient data from modalities, scanners, sequencers and databases, and provided a complete data toolkit to every team in hospital networks. Pharmacogenomics for adverse medication event prevention, and Precision Medicine application at the point of care: Incorporates sources of drug-gene interaction data that were previously only available in in accessible formats (e.g. tables in a PDF document), implementing the major Pharmacogenomic databases (like PharmGKB, CGI, DGIdb, OpenTargets...) Allows the user to refine their query to certain gene families, types of interactions, classes of drugs, etc. Flexible AI means you can choose the data set that best fits your use case, and apply it to your relevant medical images.

These exquisite, intricate machines are proteins. They underpin not just the biological processes in your body but every biological process in every living thing. They’re the building blocks of life. Currently, there are around 100 million known distinct proteins, with many more found every year. Each one has a unique 3D shape that determines how it works and what it does. But figuring out the exact structure of a protein remains an expensive and often time-consuming process, meaning we only know the exact 3D structure of a tiny fraction of the proteins known to science. Finding a way to close this rapidly expanding gap and predict the structure of millions of unknown proteins could not only help us tackle disease and more quickly find new medicines but perhaps also unlock the mysteries of how life itself works.

We are a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering to industrialize drug discovery. Increased control over biology with tools such as CRISPR genome editing and synthetic biology. Reliable automation of complex laboratory research at an unprecedented scale using advanced robotics. Iterative analysis of, and inference from, large, complex in-house datasets using neural network architectures. Increasing elasticity of high-performance computation using cloud solutions. We are leveraging new technology to create virtuous cycles of learning around datasets to build a next-generation biopharmaceutical company. A synchronized combination of hardware, software and data used to industrialize drug discovery. Reshaping the traditional drug discovery funnel. One of the largest, broadest and deepest pipelines of any technology-enabled drug discovery company.

We use our AI engine to transform drug discovery. Our discoveries help create better medicines faster. Our AI-enabled discovery portfolio includes wholly-owned and co-developed pipeline assets, and is backed by prominent investors. Atomwise developed a machine-learning-based discovery engine that combines the power of convolutional neural networks with massive chemical libraries to discover new small-molecule medicines. The secret to reinventing drug discovery with AI is people. We are dedicated to developing the best AI platform and using it to transform small molecule drug discovery. We have to tackle the most challenging, seemingly impossible targets and streamline the drug discovery process to give drug developers more shots on goal. Computational efficiency enables screening of trillions of compounds in silico, increasing the likelihood of success. Demonstrated exquisite model accuracy, overcoming the challenge of false positives.

AIDDISON™ drug discovery software combines the power of artificial intelligence (AI), machine learning (ML), and 3D computer-aided drug design (CADD) methods to act as a valuable toolkit for medicinal chemistry needs. As a unified platform for efficient and effective ligand-based and structure-based drug design, it integrates all the facets for virtual screening and supports methods for in-silico lead discovery and lead optimization.

Altis Labs announces launch of Nota – a clinical information platform to accelerate therapeutic R&D Nota leverages. AI to predict patient outcomes from imaging data so sponsors can better prioritize their most promising therapies. Nota enables researchers to operationalize clinical trial imaging data, access predictive imaging biomarkers, and accelerate R&D at scale. Using Altis’ cloud-based software platform powered by deep learning, biopharma can incorporate comprehensive outcome predictions at the image, patient, and cohort level to improve clinical trial design and more confidently anticipate clinical endpoints. Such insights have the potential to significantly accelerate development timelines, lower drug development costs, and improve the likelihood of trial success across therapeutic areas.

Optimize hospital’s antimicrobial usage by empowering prescribers & ASP members with our AI-powered software, ZEVAC. Antibiotic resistance is one of the biggest public health challenges of our time. ZEVAC is an AI-powered Next-Gen AMS software designed to help hospitals stop inappropriate or unnecessary antibiotic usage. ZEVAC’s unconventional but very scientific approach in the fight against AMR growth. Help Clinicians choose the most appropriate empiric antibiotic therapy with ZEVAC’s highly accurate & personalized antibiotic susceptibility predictions, based on patient’s information (demographic & clinical), hospital’s local prevalence, susceptibility patterns & historic culture results. Help your ASP members take proactive measures to avoid inappropriate antimicrobial usage with ZEVAC’s AI-driven insights, collated by analyzing hospital-wide clinical data in real-time.

Using RNA sequencing (RNA-seq) data and Artificial Intelligence are both a necessity and an opportunity to develop therapeutics that target splicing errors. The use of machine learning enables us to discover new splicing errors and quickly design therapeutic compounds to correct them. SpliceCore is our dedicated AI platform for RNA therapeutics discovery. We developed this technology platform specifically for the analysis of RNA sequencing data. It can identify, test and validate hypothetical drug targets faster than traditional methods. At the heart of SpliceCore is our proprietary database of more than 5 million potential RNA splicing errors. It is the largest database of splicing errors in the world and it is used to test every RNA sequencing dataset that is input for analysis. Scalable cloud computing enables us to process massive amounts of RNA sequencing data efficiently, at higher speed and lower cost, exponentially accelerating therapeutic innovation.

Discover biological biomarkers, create insights into disease mechanisms, discover new drugs or identify changes in protein levels from a set of carefully designed experiments. We’ve made it easy to start unlocking the power of MS and Proteomics so you can focus on the biological complexity and move closer to the moment of discovery. Our automated and repeatable workflow allows for quicker experiment startup and turnaround times, giving you the control and flexibility to make and act on decisions in the moment. Allowing you to focus on biological insights and human-to-human collaboration, our proteomics data processing workflow is built to scale, repeatedly. We’ve pushed heavy and repetitive processing to the cloud, enabling a seamless and enjoyable experience. Our intelligent Proteomics workflow seamlessly integrates complex moving parts to enable larger experiments to be processed and analyzed with ease.

Patients from around the world suffer from complex diseases and a staggering variety of symptoms. However, they share one thing in common: Patients have a need for faster development of safer and more effective therapies. Owkin’s mission is to empower researchers in hospitals, universities, and pharmaceutical companies to: understand why drug efficacy varies from patient to patient, enhance the drug development process, and identify the best drug for the right patient to improve treatment outcomes. Owkin Loop is the foundation of Owkin’s research platform: it connects medical researchers with high-quality datasets from leading academic research centers around the world. Owkin Loop is powered by the two main components of Owkin’s Software Stack: Owkin Studio, our machine learning platform, and Owkin Connect, our federated learning framework. Owkin medical research collaborations are in Oncology, Immunology and Cardiovascular diseases.

Scitara DLX™ offers a rapid connectivity infrastructure for any instrument in the life science laboratory in a fully compliant and auditable cloud-based platform. Scitara DLX™ is a universal digital data infrastructure that connects any instrument, resource, app and software in the laboratory. The cloud-based, fully auditable platform connects all data sources across the lab, allowing the free flow of data across multiple end points. This allows scientists to devote their time to scientific research, not waste it solving data issues. DLX curates and corrects data in flight to support the development of accurate, properly structured data models that feed AI and ML systems. This supports a successful digital transformation strategy in the pharma and biopharma industries. Unlocking insights from scientific data enables faster decision-making in drug discovery and development, helping bring drugs to market more quickly.

Medical AI is a true technology solution that comprehensively addresses chronic diseases. The hallmarks of this technology are its ability to predict, generate the next-best actions, and present the outputs in an easy-to-consume user experience. DeLorean Medical AI augments human capabilities and creates a future where we can trust both the machine and the human to make the best decisions. Our technology has been shown to improve outcomes and is the first AI to be biologically validated through third-party clinical tests. With the ability to better classify patient populations, assign risk, and predict disease state transitions, Medical AI directly leads to earlier detection and diagnosis of diseases. It can also reduce costs. Having been installed for 10+ clients, it has demonstrated both cost reductions and savings associated with real-time predictions to determine at-risk populations and next-best-action recommendations based on statistical probabilities.

The cost, complexity and long timeframes associated with evidence generation through traditional approaches prevent agile research and the broader utilization of authentic patient insights in the treatment development and commercial pipelines. Our HyperStream represents the largest real-time patient experience data stream on earth. It captures the real-world digital history of diseases, as they are shared by authentic patients online. Pharos is a web-based evidence generation tool and research framework that uses its integrated data streaming and AI capabilities to efficiently capture online patient experience data and enables teams to quickly discover evidence when they need it. To date, the Pharos Suite has successfully been used to generate evidence and patient insights in multiple therapy areas and diseases.

Deliver personalized patient care with the only histologically validated, objective, and quantitative CTA-based arterial analysis software. Utilize ground-truth histology to visualize the source of myocardial ischemia and inform heart attack and stroke risk. Heart attack and stroke are primarily caused by non-obstructive, but unstable plaque in the arteries that goes undiagnosed and untreated. Current non-invasive testing cannot visualize the biology deep inside artery walls where heart disease develops. Elucid is harnessing scientific imaging and artificial intelligence to enable quick, accurate, noninvasive diagnoses and precise treatment of cardiovascular disease to enable better patient outcomes. Assess plaque composition with histology-validated software. Quantify heart attack and stroke risk with greater accuracy. Visualize a comprehensive and objective view of arterial disease to enable personalized treatment plans before a patient ever enters the hospital.

NVISO is a global leader in human behaviour artificial intelligence (AI) software serving manufacturers of user-centric products and services worldwide. Globally deployed and validated human behaviour AI technology with high accuracy for key applications in making autonomous vehicles (e.g. Tesla EVs) safe with interior monitoring, patient monitoring for remote tele-medicine in healthcare/ robotics, and intelligent devices for smart homes. Enabling financial advisors to provide best interest advice with scientifically validated tools which detect and help manage client behaviours. Enhancing the safety, security, and comfort of connected and autonomous vehicles with advanced driver and occupant detection, authentication, and monitoring. Empowering medical professionals with intelligent patient monitoring to drive better patient outcomes while improving efficiency in aged-care homes and hospitals.

Facilities use Volpara Health software for early detection of breast cancer, including top US cancer screening centers. Mammography technologists rely on Volpara Health to improve mammogram quality. The most scientifically validated screening software in the breast health industry. Volpara gives you the evidence you need, right when you need it. Access to patient data for more informed breast cancer risk assessment. Each and every image we analyze improves our algorithms for early detection of breast cancer. Your aid in advocating for additional screening or genetic testing of patients. Build worklists and reports to individual preferences. Simultaneously access stats and lists from a single screen. Standardize communications for patients, referrers, and insurers. Send more compelling result letters with mammogram thumbnail images.

Plug’n play API to integrate with your diabetes management platform. Personalized therapeutic education. Better insights on BGL fluctuations. Real-time prediction to anticipate risks. Allow for more personalization and better regulation of the system. Handle complex living phases with rapid glucose changes. Telemedicine & retrospective analysis. Decision-support for patients. Hillo is currently working on the next versions of its AI technology, a therapeutic recommendation system to anticipate and prevent hypoglycemia and hyperglycemia, whose CE mark class IIB is planned for 2020, and the new generation of artificial pancreas(AP) for 2021, which will help overcome the main limitations of current AP systems thanks to the ultra-personalization provided by machine learning. The first self-learning artificial intelligence for predicting blood glucose levels to obtain CE mark as a medical device.

Wayfinder is the all-in-one, SaaS big data platform for healthcare and life sciences, unifying data, analytics, and AI workloads into an ecosystem that accelerates the time to insights for the healthcare and life sciences industries. Wayfinder makes it possible to find granular insights from healthcare data faster. Built on the Databricks Lakehouse platform, Wayfinder delivers access to over 45 terabytes of de-identified, remastered claims data and meets the unique data and processing needs of the healthcare and life sciences industries at scale. With Wayfinder, you can analyze higher-quality claims data to identify rare patients, and target providers, build comprehensive patient journeys, and identify market trends, all with granular detail to inform strategies that drive differentiation and growth. Wayfinder is your big data infrastructure, so you can stop preparing and managing your data and start analyzing.

NVIDIA® Parabricks® is the only GPU-accelerated suite of genomic analysis applications that delivers fast and accurate analysis of genomes and exomes for sequencing centers, clinical teams, genomics researchers, and high-throughput sequencing instrument developers. NVIDIA Parabricks provides GPU-accelerated versions of tools used every day by computational biologists and bioinformaticians—enabling significantly faster runtimes, workflow scalability, and lower compute costs. From FastQ to Variant Call Format (VCF), NVIDIA Parabricks accelerates runtimes across a series of hardware configurations with NVIDIA A100 Tensor Core GPUs. Genomic researchers can experience acceleration across every step of their analysis workflows, from alignment to sorting to variant calling. When more GPUs are used, a near-linear scaling in compute time is observed compared to CPU-only systems, allowing up to 107X acceleration.

We are an artificial intelligence-enabled SaaS that diagnoses drug-resistant tuberculosis in a few hours. AarogyaAI aims to diagnose drug-resistant tuberculosis (DR-TB) using Artificial Intelligence in a few hours. We enable quick and accurate diagnosis of DR-TB so that the patient can be rightly prescribed effective drug combinations for treatment, instantly. Tuberculosis claims more lives every year than AIDS. This is because, of the 19 anti-TB drugs available, doctors don’t always know which ones will work for whom. Thus, even though tuberculosis is curable, a delayed diagnosis of drug-resistant tuberculosis can mean patients are on ineffective medication for up to 7 years. AarogyaAI aims to diagnose drug-resistant tuberculosis in a few hours so that a patient can be prescribed effective treatment, instantly. We use a DNA sequence from the patient which is uploaded to our SaaS. Our machine learning algorithm then gives an output report of a comprehensive drug susceptibility status.

Accuracy, speed, confidence. Introducing generative AI to commercial biopharma. Simplify the labor-intensive process of collecting, organizing, and inspecting vast amounts of complex data. Get straight to decision-critical insights with 100% confidence, every time. With our AI-powered data manipulation and verification platform, you'll never lose track of your workstreams again. Gather, refine, and check your data, all in one place. Search public and private databases by key drug characteristics. Segment drugs and trials by detailed patient profiles. Extract the data you need in plain English. Support your findings by linking answers back to their source. Focus your time and energy on synthesizing high-quality outputs from data rather than menially sifting through it. Our specialized LLMs enable researchers to perform asset scans 4.8x faster than by hand. We index over 38M scientific publications, conference abstracts, and clinical trials. All the data you need, when you need it.

At Genospace, we understand that genomics is driving the development of precision medicine, yet scaling its delivery is an unsolved challenge. We’re here to help. Our platform is designed to make biomedical data meaningful and accessible to everyone, especially those on the front lines of care delivery. Arm your clinicians and researchers with the information they need to make informed decisions and join us in our mission of leveraging high-dimensional molecular data to improve individual patient outcomes and accelerate drug development and research. Large-scale population data is necessary for drug development and research. Conduct cohort-driven analyses to inform your research activities with the Genospace platform. We specialize in clinical trial research. Use the Genospace platform to match fragmented patient data to complex trial criteria and expedite patient accruals. Integrate genomic medicine into mainstream clinical care with the Genospace platform.

Artificial intelligence to transform healthcare diagnosis. Using AI and predictive analytics for early-stage disease detection and accurate diagnosis. Cloud-enabled AI platform to ensure affordable and accessible healthcare for all. Endimension Technology is a healthcare artificial intelligence startup incubated at IIT Bombay. We develop AI algorithms to automatically detect abnormalities and diseases from medical scans. The founding team consists of machine learning researchers, software engineers and medical doctors from reputed institutions. Our mission is to build healthcare AI technology products that will reduce patient misdiagnosis. AI to reduce radiologist workload and improve patient turnaround time.

BioNeMo is an AI-powered drug discovery cloud service and framework built on NVIDIA NeMo Megatron for training and deploying large biomolecular transformer AI models at a supercomputing scale. The service includes pre-trained large language models (LLMs) and native support for common file formats for proteins, DNA, RNA, and chemistry, providing data loaders for SMILES for molecular structures and FASTA for amino acid and nucleotide sequences. The BioNeMo framework will also be available for download for running on your own infrastructure. ESM-1, based on Meta AI’s state-of-the-art ESM-1b, and ProtT5 are transformer-based protein language models that can be used to generate learned embeddings for tasks like protein structure and property prediction. OpenFold, a deep learning model for 3D structure prediction of novel protein sequences, will be available in BioNeMo service.

InformAI has a healthcare focus on AI solutions that speed up medical diagnosis at the point-of-care and improve radiologist productivity. Our AI-enabled image classifiers and patient outcome predictors are developed within the world’s largest medical center complex, the Texas Medical Center. Together with our partners, InformAI is transforming the way healthcare is being delivered. InformAI works with renowned healthcare organizations, national physician groups, and leading medical imaging companies to build solutions that improve patient outcomes. Our team is comprised of leaders in healthcare, medicine and artificial intelligence. The InformAI Sinus Image Classifier is built using a 3D convolutional neural network (CNN) trained on a radiology-validated 3D CT-scan image library consisting of 6 million medical images.

The software that will help you improve the safety, traceability, quality, agility and integration of your Pharmacotechnics and Medicines Manufacturing Unit. No two pharmacy services are the same, which is why we have divided PharmaSuite into functional modules that will help you manage the different units in the most efficient way. Management of the Pharmacotechnics and Drug Preparation unit (parenteral mixtures). Management of parenteral nutrition.

Diagnosis is the process of determining which disease or health condition explains a person's test results and symptoms. DDxHub - Differential diagnosis Hub is the System distinguishing of a particular disease or health condition from others that present similar symptoms and lab test results. DDxHub is a concentrator that holds a lot of disease descriptions. DDxHub is useful when you try to find a right diagnosis by comparing several different possible diagnoses. You may enter your own disease definition into DDxHub repository and share the disorder descriptions with other DDxHub users around the world. In turn, you will be updated with disorder descriptions from other DDxHub users. Join the thousands healthcare professionals and patients who already love DDxHub's differential diagnosis, sync, and disorders description sharing solution. DDxHub is useful for clinical therapeutics students at medical schools as educational resource.

Rare diseases are often not well studied and there is a limited understanding of many of the aspects necessary to support a drug discovery program. Our AI platform, Healnet, overcomes these challenges by analyzing millions of drug and disease data points to find novel connections that could be turned into new treatment opportunities. By applying frontier technologies across the discovery and development pipeline, we can run multiple stages in parallel and at scale. One disease, one target, one drug: it's an overly simple model, yet it's the one used by nearly all pharmaceutical companies. The next generation of drug discovery is AI-powered, parallel and hypothesis-free. Bringing together the key three drug discovery paradigms.

Democratizing expert cardiac care through medical-grade AI and cloud technology. Cardiologs' unique Arrhythmia diagnostic software is cloud-based, vendor-neutral and powered by Artificial Intelligence. AI carries the promise of a future where healthcare professionals have intelligent tools in hand and patients have access to the best care. Cardiologs algorithms are clinically validated and can detect more than 20 types of arrhythmia events. Cardiologs aims to make cardiology diagnostics scalable and accessible to everyone, and provide tools for clinicians across the globe to face the increased demand for cardiological diagnosis. At Cardiologs, we value passionate and enthusiastic individuals, who are excited by the idea of advancing medical technology. Knowing that our contribution will make a difference in the life of patients and healthcare professionals drives us to do our best every day. We are pioneering the development of medical-grade AI.

Generate DDx and clinical plans with Glass AI. Access our community library of shared medical knowledge. Build and maintain medical knowledge in a platform optimized for understanding and retention. Make the most of every case and didactic in a notetaking system designed for clinical medicine. Lift up colleagues and trainees by effortlessly sharing schemas, scripts, and cases. Quickly capture and sort knowledge pearls that surface on busy days and later link them to relevant pages. Deepen and refine your knowledge by capturing learning points from cases. Effortlessly connect concepts and pages together to reflect and navigate sophisticated mental models. Share knowledge with colleagues in a clean and simple format. Import your existing notes from Evernote (other integrations coming soon) Join the Glass Health community and help us build a new generation of powerful and frictionless software for clinicians.

Healthcare professionals & pharmaceutical companies use RetinAI's software platform discovery to manage their data, gain enhanced insights with automatic AI analysis, and supercharge clinical and research workflows. A single data platform to manage & access your data anytime from anywhere. Compatible formats include DICOM-compliant and proprietary formats. Data is harmonized, organized, aggregated & analyzed at scale using AI to extract insights about disease progression, treatment outcomes & progression prediction. Enable participative research across your organization with secured cloud-based access to data. The town square for data, medical, and digital teams. Perform AI-based analysis on your OCT volumes for layer & fluid segmentation. Provide immediate evaluation & centralize your insights in a single platform. Instantly invite collaborators to access and work with datasets with different permission levels.

The microbiome is implicated in numerous diseases and health conditions. Learn how Kaleido is leading a differentiated approach to translating the promise of the microbiome into solutions for patients. The human microbiome is a community of more than 30 trillion microbes, organisms that include bacteria, viruses, archaea and fungi, which reside on and inside the human body. Over the last decade, research has increased exponentially on the impact the microbiome has on human health, including cardiovascular disease, cancer, diabetes, Parkinson’s disease and allergies. This highly complex microbial ecosystem has been referred to as a “newly discovered organ.” Many other human organs command tens of billions of dollars for therapeutics that treat disease by modulating physiology. From a therapeutic perspective, the microbiome organ remains a largely untapped frontier in healthcare.

Corti believes that technology augments human strengths and that it's a fundamental obligation to build such technology to enable healthcare to keep doing more, with less. Audia was built to allow medics improve patient outcomes and internal performance across healthcare systems. Integrate Audia into your healthcare systems and start recording your medical consultations, receiving continuous improvement. Whatever video platform you utilize, Audia can instantly plug into your existing systems and start recording your medical consultations. Audia can help to utilize written information by analyzing and powering any textual interaction, such as a chatbot integration. Start uploading your consultations to Audia today to receive unique insights on consultations in order to improve triage, internal performance and understanding health trend.

Our AI products are designed to empower healthcare professionals during key moments in the medical journey. From preventive screenings, early detection, emergency care, institutional disease response and treatment adherence; we're enabling seamless workflow optimization across the care continuum. Collaborating with world-renowned healthcare experts, and training algorithms on unprecedented volumes of data, our AI is developed to uphold the strictest global regulatory standards. Backed by deep data science research our solutions anticipate care needs to aid you in constrained circumstances. Our AI solutions are ready for deployment, whenever and wherever needed. Designed to integrate with existing technological infrastructure, they are configurable with your devices of choice. We offer convenient deployment and scaling procedures while assuring industry-certified data security. Our team is there to support you every step of your AI journey.

Our regulatory compliant platform empowers clinical research by algorithmically analyzing unstructured EMR data for life endangering conditions. We build technologies that expand access to the most Innovative Healthcare through Clinical Trials. We are a team focused on saving lives by providing access to healthcare therapeutic innovations that are still under investigation. We believe that every patient should be empowered and educated on their opportunities to participate in clinical trials that may offer therapies significantly saving or improving their lives. We are an advanced healthcare AI research company that have developed a computational-based platform to identify patients who match a complex set of criteria to participate in clinical trials.

Many decisions in cancer care are uncertain and current tools are not helping the majority of cancer patients. This is leading to unnecessary loss of life and billions of dollars of wasted cost. We are a team of multidisciplinary computer scientists and oncologists helping tackle the most pressing questions in cancer care through AI. We are building clinical grade deep learning to analyze each patient's characteristics and provide clarity to oncologists during decision making. Our AI is built with oncologists at the center and provides interpretable and actionable insights. We work with top academic medical centers and community oncologists to answer clinically important questions.

We believe that Waveform AI can help the healthcare system in so many ways, and we’re building a platform to empower clinicians with useful information and support across the care continuum. “It takes a village” to transform healthcare, and to contribute to advancing the field, we’re publishing peer-reviewed AI research to show where and how AI will benefit every step of the patient care journey. Help providers identify patients with a high risk for sleep apnea using data from EMR, waveforms, wearables, and a multitude of sources and refer patients for diagnosis. Use data to help providers identify the most critical patients in the massive undiagnosed population by stratifying patients by risk for adverse outcomes and potential costs. Help clinicians bring patients through the diagnostic process and get more patients treated more quickly by optimizing efficiency, cost, and quality of sleep apnea diagnosis.

VeraChem LLC was founded in 2000 to advance the state of the art in computer-aided drug discovery and molecular design by developing computational chemistry methods that are based on cutting-edge basic science but are also applicable in applied science research settings. Efficient high-performance software implementations of these methods coupled with comprehensive user support are a central company strategy for product development. Current VeraChem software capabilities include protein-ligand and host-guest binding affinity prediction, fast calculation of accurate partial atomic charges for drug-like compounds, computation of energies and forces with all the commonly used empirical force fields, automatic generation of alternate resonance forms of drug-like compounds, conformational search with the powerful Tork algorithm, and automatic detection of topological and 3D molecular symmetries. VeraChem’s software packages are constructed from a modular code base.

adWATCH - AE helps pharmaceutical organizations manage and report adverse events that occur during clinical trials. adWATCH - AE gives the reporter at a clinic, hospital, or investigative site a fast and effective means of generating and managing Adverse Event Reports (AERs) and reporting to the regulatory departments and government agencies. An adverse effect is a negative or dangerous effect experienced by a patient and caused by drugs and/or medical devices. Adverse event reporting requires the tracking of all medical complaint case information, resulting in the generation of MedWatch reports, CIOMS reports and additional reports for management. adWATCH - AE allows researchers, physician investigators, Contract Research Organizations (CROs), clinical trial specialists, and other health professionals to produce and file AERs in the FDA mandated MedWatch and/or CIOMS format.2

Transform drug discovery and materials research with advanced molecular modeling. Our physics-based computational platform integrates differentiated solutions for predictive modeling, data analytics, and collaboration to enable rapid exploration of chemical space. Our platform is deployed by industry leaders worldwide for drug discovery, as well as for materials science in fields as diverse as aerospace, energy, semiconductors, and electronics displays. The platform powers our own drug discovery efforts, from target identification to hit discovery to lead optimization. It also drives our research collaborations to develop novel medicines for critical public health needs. With more than 150 Ph.D. scientists on our team, we invest heavily in R&D. We’ve published over 400 peer-reviewed papers that demonstrate the strength of our physics-based approaches, and we’re continually pushing the limits of computer modeling.

Spin practice data into profit, practitioner performance, and patient health with computer vision-enabled clinical performance insights from the world’s most advanced AI-powered pathology detection engine. Trained on the largest collection of expertly annotated dental imagery in the world, Pearl’s computer vision system reads radiographs with the accuracy of an expert dentist and the speed and consistency of a machine. Practice Intelligence® puts Pearl’s AI to work for dental offices to deliver potent clinical insights that dental offices leverage across every stage of their workflow to boost patient care and practice performance. Automatically distinguish tooth parts and supporting structures for more localized and qualitative radiologic insight. Precisely assess the size of anatomical structures, the extent of bone loss, and progression of decay. Approve/reject AI detections or add additional findings to ensure that what patients see reflects the clinician’s findings.

BC platforms leverages latest science, unique technology capabilities, and strategic partnerships to achieve our mission of revolutionizing drug discovery and personalizing care. Modular, highly configurable platform for integrated healthcare data. Open analytics framework seamlessly combining latest innovative methods, analytics and technology developments in one single platform. Superior security: ISO 27001 certified, GDPR and HIPAA compliance. Complete product portfolio enabling a modern healthcare system to fully embrace personalized medicine. Scalable deployments enabling a robust start as well as large scale healthcare operation. Accelerated translation of research insights into clinical practice with our unique end to end toolbox. We help reduce your risk, enhance your pipeline value and advance your enterprise data strategy by solving the barriers of data access and enabling rapid insight generation.

DNAnexus Apollo™ accelerates precision drug discovery by unlocking the power of collaboration to draw critical insights from omics data. Precision drug discovery requires collecting and analyzing huge volumes of omics and clinical data. These datasets are incredibly rich resources, but most legacy and home-grown informatics tools can't cope with their size and complexity. Precision medicine programs can also be hampered by siloed data sources, underpowered collaboration tools, and the burden of complex and always changing regulatory and security requirements. DNAnexus Apollo™ supports precision drug discovery programs by empowering scientists and clinicians to explore and analyze omics and clinical data together, in a single environment, built on a robust, scalable cloud platform. Apollo lets them share data, tools, and analyses easily and securely with peers and collaborators everywhere - whether they're on another floor, or another continent.

Since 1985 ChemDraw® solutions have provided powerful capabilities and integrations to help you quickly turn ideas and drawings into publications you can be proud of. A chemistry communication suite, ChemOffice+ Cloud transforms your chemical drawings into chemical knowledge by facilitating the management, reporting and presenting of your Chemistry research. ChemOffice+ Cloud, is a robust, comprehensive suite, purpose-built to simplify, facilitate, and accelerate chemistry communication. The cloud-native chemistry communication suite builds on the foundations of ChemDraw Professional and adds access to a powerful set of tools to enable scientific research. The mundane task of creating reports to communicate chemical research has become much more efficient with ChemOffice+ Cloud. With powerful capabilities to search, reuse, select, and organize chemical structures and data, chemists can use ChemOffice+ Cloud to create presentation-ready PowerPoint slides and manuscripts.